Mechanistic Studies of Drug Dissolution Testing : Implications of solid phase properties and in vivo prognostic media by Lehto, Paula
1 INTRODUCTION
I
Division of Pharmaneutical Technology 
Faculty of Pharmacy
University of Helsinki
Mechanistic studies 
of drug dissolution testing 
Implications of solid phase properties                                     
and in vivo prognostic media 
by
Paula Lehto
Academic Dissertation
To be presented, with the permission of the Faculty of Pharmacy of the  
University of Helsinki, for public criticism in auditorium XII at Helsinki University 
main building (Unioninkatu 34), on February 5th, at 12 noon 2010.
II
Supervisors:  Docent Leena Peltonen
   Division of Pharmaceutical Technology
   University of Helsinki
   Helsinki, Finland
   Professor Veli Pekka Tanninen
   Pharmaceutical Product Development
   Orion Pharma R&D
   Espoo, Finland
   Professor Jouni Hirvonen
   Division of Pharmaceutical Technology
   University of Helsinki
   Helsinki, Finland
Reviewers  Docent Jarno Salonen
   Laboratory of Industrial Physics
   University of Turku
   Turku, Finland
   Professor Thomas Rades
   School of Pharmacy
   University of Otago
   Dunedin, New Zealand
Opponent:  Professor Jarkko Ketolainen
   Department of Pharmaceutics
   University of Kuopio
   Kuopio, Finland
© Paula Lehto
ISBN 978-952-10-5318-4 (paperback)
ISBN 978-952-10-6093-9 (pdf)
ISSN 1795-7079
Helsinki University Printing House
Helsinki, Finland, 2010
1 INTRODUCTION
I
acknowledgements
This thesis was carried out at the Division of Pharmaceutical Technology, Faculty 
of Pharmacy, University of Helsinki. During this study I worked at Orion Pharma 
and the experiments of the thesis were part of the In-vitro-in vivo technology 
project. I wish to thank all the people involved in this work.
My deepest gratitude goes to my supervisors, Docent Leena Peltonen, Profes-
sor Veli Pekka Tanninen and Professor Jouni Hirvonen. Docent Leena Peltonen 
has guided me towards being an independent and critical scientist. Her long 
patience and any-time availability has made my work a lot of easier. I am very 
grateful to Professor Veli Pekka Tanninen for his endless inspiration and support 
and positive attitude towards my studies. During the grazy moments of this 
study Prof. Tanninen has help me to put things into right perspective. Professor 
Jouni Hirvonen is gratefully acknowledged for sharing of his expertise and en-
couraging me to go further with the studies.
The reviewers of this thesis, Docent Jarno Salonen and Professor Thomas 
Rades, are warmly thanked for extremely flexible and quick review process and 
their constructive comments on the manuscript.
A load of thanks to my co-authors, Mikko Tenho, Jaakko Aaltonen, Pentti 
Niemelä, Hanna Kortejärvi, Anni Liimatainen and Krista Ojala for their scientific 
contribution, inspiring discussions and assistance with the experiments. Profes-
sor Jukka Rantanen is gratefully acknowledged for unselfish sharing of his ex-
pertise in the field of solid state of pharmaceuticals. I owe my special thanks to 
Anja Koski for fruitful discussions concerning dissolution testing and her friend-
ship throughout this work.
I thank Orion Pharma, and especially Jarmo Lintulaakso, Tuula Romppanen 
and Tuula Hokkanen for providing me the opportunity to carry out the Ph.D. 
studys at Orion Pharma. Tero Närvänen is warmly thanked for his friendly sup-
port and interest towards my studies. My special thanks to all who worked in 
Orion’s laboratory of physics during 2006-2008.
I owe my deepest gratitude to my parents, Lena and Markku, and my sister’s 
family (Katri, Tuomo, Julia, Elise and Sofia), for always being there for me. I 
warmly thank my mother-in-law, Milja, for being such a good listener and sup-
port. All my friends are thanked for understanding that I did not have much free 
time during these years of the Ph.D. study. 
Finally, I thank my most lowed ones, Ilkka, Aino and Vijami, for everything. 
With you I am whole. With you my dream have came true.  
Helsinki, February 2009
Paula Lehto (née Heinänen)
II
  
1 INTRODUCTION
III
abstract
Drug absorption after oral administration requires that the drug first dissolves 
into gastro-intestinal tract liquids. In vivo dissolution of a drug is affected by 
physiological and drug-related physicochemical factors. In the case of poorly 
water-soluble drugs, in vitro dissolution testing at various stages of drug devel-
opment is especially important, since the absorption is predominantly limited 
by the dissolution rate. Varying dissolution rates, possible for different physical 
structures of the same chemical entity (known as polymorphs), for example, can 
lead to varying degrees of bioavailability and, potentially, result in therapeutic 
failure. Traditionally, pharmaceutical dissolution testing has relied on determi-
nation of the dissolved drug concentration from liquid phase. This has led to 
poor understanding (and possible underestimation) of the connection between 
the change in solid phase and dissolution behaviour. Thus, new powerful ap-
proaches are needed. To correlate in vitro dissolution results of drug products 
with in vivo behaviour often requires the use of dissolution methods reflecting 
conditions in the gastro-intestinal tract. For such purpose, various physiologi-
cally based dissolution media have been proposed.
In this thesis, solid phase analysis was combined with dissolution determina-
tions to provide in depth understanding of the effects of solid state properties 
on the intrinsic dissolution rate of active pharmaceutical ingredients (API). A 
new approach to dissolution testing, which involved simultaneous in situ solid 
phase analyses of the dissolving sample and measurement of dissolved concen-
trations in the dissolution medium, were utilized to explain the implications of 
solvent-mediated solid phase conversions on dissolution processes. Simplified 
dissolution media were developed and studied for the prediction of in vivo be-
haviour of Biopharmaceutics Classification System (BCS) class II drugs.
Quantitative solid phase analysis using Raman spectroscopy was successfully 
performed in situ during the intrinsic dissolution testing of APIs. Direct solid 
phase analysis in tandem with measurement of dissolved concentrations enabled 
molecular level insight into changes in dissolution rate due to hydrate forma-
tion. Against expectations, preferred orientation of drug crystals during sample 
preparation was shown to have only minor effects on dissolution results dur-
ing intrinsic dissolution. Importance of dissolution medium on solvent-mediated 
conversion kinetics was revealed as bile salts were shown to be able to interact 
with the dissolving solid by hydrogen bonding mechanisms. To predict in vivo 
behaviour of BCS class II drugs, simple and cost-effective conventional surfactant 
media were shown to be potential substitutes for more complex, physiologically 
based Fasted State Simulated Intestinal Fluid (FaSSIF).
This thesis provides directly applicable new tools for the dissolution experi-
ments in pharmaceutical drug development. In-depth information of solid state 
properties on dissolution rate assists in drug candidate selection as well as in 
explaining and controlling the behaviour of APIs in the final drug products. 
IV
The use of simplified, in vivo prognostic dissolution media has potential of sav-
ing development time and costs for formulation development and regulatory 
purposes.
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1 INTRODUCTION
1
1 introduction
More than eighty percent of the best-selling pharmaceutical products today are 
administered by the oral route (Lennernäs and Abrahamsson, 2005). Due to ad-
vances in combinatorial chemistry and high throughput screening, more than 
40% of the newly discovered active pharmaceutical ingredients (API) exhibit 
high lipophilicity and often also high activity, but poor water-solubility (Lipinski, 
2000; Connors and Elder, 2004). As a result, dissolution into gastro-intestinal (GI) 
tract liquids, which is recognized as a prerequisite for absorption into the sys-
temic blood stream, has became a major challenge for oral delivery (Dressman 
et al., 2007; Stegman et al., 2007). Perception of potential bioavailability (BA) 
problems is crucial as early as possible, since considering the long drug develop-
ment cycles of 8–12 years and high R&D costs (over US $800 million (DiMasi et 
al., 2003)), failure in the late clinical phases would be economically unprofit-
able, not to mention the exposure of healthy human volunteers in unnecessary 
pharmacokinetic studies. To assist successful oral drug development, in vitro dis-
solution testing has emerged as a preferred method to evaluate development 
potential of new APIs and drug formulations (figure 1).
Figure 1. Roles of in vitro dissolution testing in pharmaceutical drug develop-
ment.
At the early stage o f development, typically called the preformulation stage, 
dissolution testing of pure APIs serves as a strategically important tool to evalu-
ate the physicochemical properties of drug candidates and to select the most 
appropriate solid form for further development. Overall, inconsistent solid form 
properties, such as suddenly appearing polymorphic forms or solid phase trans-
formations, are often the root cause for batch-to-batch variation in manufactur-
ing (Shekunov and York, 2000; Zhang et al., 2004). When dealing with poorly 
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2soluble drugs, even slight changes in dissolution behaviour may lead to inad-
equate bioavailability and delay new drug approvals as well as cause product 
recalls from the market (Meyer et al., 1992; Vippagunta et al., 2001). In addition, 
observations of potential solubility/dissolution-limited absorption phenomena 
can strongly facilitate and direct formulation strategies at this stage of develop-
ment. 
At later stages of development, dissolution tests are performed with drug 
products to compare prototype formulations, to indicate stability and the suc-
cess of the manufacturing process, and to assure safe release of the products to 
the market. With the introduction of regulatory guidelines concerning Biophar-
maceutics Classification System (BCS) (FDA, 2000) and establishment of in vitro-
in vivo correlation (IVIVC) (FDA, 1997b; EMEA, 2000), the focus of dissolution 
testing has rapidly moved from a traditional ‘single point’ quality control test to 
a critical indicator of medicaments performance in vivo. Especially in the cases of 
dissolution-controlled absorption (BCS class II drugs), it is of major importance to 
search for an IVIVC. Validated ‘point-to-point’ IVIVC models enable not only the 
prediction of absorption profiles, but also the utilization of dissolution tests as 
surrogate measures for bioequivalence (BE) (called biowaivers). 
Prediction of in vivo behaviour often requires the use of in vitro dissolution 
methods reflecting the in vivo GI conditions. Several physiologically based disso-
lution media, like Fasted State Simulated Intestinal Fluid (FaSSIF) and Fed State 
Simulated Intestinal Fluid (FeSSIF) (Galia et al., 1998; Jantratid, 2008), have been 
proposed for this purpose, but their prediction accuracy is still insufficient in 
many cases. One of the main reasons is the complexity of the physiology of 
the GI tract (e.g. hydrodynamics) and the digestion process, which are not yet 
completely understood. In addition, the pharmaceutical industry has been re-
luctant to make use of the more complex and expensive dissolution media. The 
lack of innovativeness in employing the available dissolution testing methods is 
mainly due to the conservative regulatory environment (FDA, 1997a). Although 
the advised compendial dissolution methods are well-suited for the traditional 
quality control purposes, they may not be able to answer other challenging de-
mands faced during drug product development. For example, by relying solely 
on the detection of drug concentrations in the liquid state, problematic dissolu-
tion behaviour of APIs undergoing solvent-mediated phase conversion during 
the dissolution cannot be completely addressed. Hopefully, the new regulatory 
‘Quality by Design (QbD)’ directives (FDA, 2004a; FDA, 2004b; ICH Q8, 2005a; ICH 
Q9, 2005b), which encourage pharmaceutical development for in-depth under-
standing of ‘causes and consequences’, will lead to even more innovative and 
science-based approaches in order to ensure the dissolution consistency of the 
oral dosage forms in human body.
In this thesis, mechanistic in-depth approaches are used to study the early 
phase dissolution testings of pure APIs and drug formulations. Novel methods 
comprising simultaneous liquid and solid phase detection during the dissolution 
testing are demonstrated. In addition, an industrial perspective is provided in 
the application of in vivo prognostic dissolution media.
2 THEORY AND LITERATURE REVIEW
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2 theory and literature review
2.1 concept of dissolution
Dissolution is defined as a dynamic process by which a material is transferred 
from solid state to solvent phase per unit time. Figure 2 is a schematic represen-
tation of the dissolution process. At the first stage (a and b) a solute molecule 
is removed from its solid phase and a cavity for the molecule is created in the 
solvent. In the second stage (c) molecules of the solute are inserted into solvents 
cavities and the solute and solvent molecules bind to each other (Brittain and 
Grant, 1999). For the process to proceed spontaneously, the forces of attraction 
between the solute and solvent must overcome the attractive forces holding 
together the solid and the liquid solvent (Byrn et al., 1999). The term solubility 
is used for a specific thermodynamic parameter, which in specified conditions 
(temperature, pressure, solvent, pH) is constant. The term dissolution is applied 
for a kinetic parameter, which presents the amount of drug that transfers from 
solid state to solvent phase per unit time.
 3
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Figure 2. Steps of dissolution process. Modified from Abraham et al., 2002.
Drug absorption after oral administration requires that the drug dissolves into 
the gastro-intestinal fluids. The theoretical expression most often used to de-
scribe the dissolution rate is the Noyes-Whitney equation (Noyes and Whitney, 
1897), which was published over one hundred years ago, but is still valid:
 
 
 
 
( )ts CCh
AD
dt
dm −⋅⋅= )(
                                                            
    (1)
where D is the diffusion coefficient of the drug substance in a stagnant layer of 
dissolution medium around each drug particle with thickness h, A is the drug 
particle surface area, Cs is the saturation solubility and Ct is the drug concentra-
tion in the bulk solution. The most important physicochemical and physiological 
parameters affecting drug dissolution in the GI tract are summarized in table 1. 
4In addition, formulation dependent parameters also influence the dissolution 
of drug products (Dressman et al., 1998; Dressman and Krämer, 2005). Continu-
ous removal of a drug from the intestine due to the absorption through the 
intestinal wall usually assures in vivo that the concentration in the bulk solution 
is negligible compared to saturation solubility (Ungell and Abrahamsson, 2000). 
To achieve physiologically representative dissolution results, this state – denoted 
as ‘sink condition’ – is widely recommended for all in vitro dissolution testing 
(USP XXXI, 2008; FDA, 1997a). 
Table 1. Factors affecting drug dissolution in the gastro-intestinal tract. 
Modified from Dressman et al., 1998.
factor (noyes-Whitney 
equation)
Physicochemical Parameter Physiological Parameter
Surface area of drug (A) Particle size, wettability Surfactants in gastric and intes-
tinal liquids
Diffusivity of drug (D) Molecular size Viscosity of luminal contents, 
micelle size of amphiphiles
Boundary layer thickness (h) Motility patterns and flow rate
Solubility (Cs) Hydrophilicity/hydrophobic-
ity, pKa, melting point, crystal 
structure,  solubilization, com-
plexation
pH, buffer capacity, bile, food 
components
Amount of drug already dis-
solved (Ct)
Permeability across gut wall
Volume of solvent available (Ct) Secretions, co-administered 
fluids
2.2 dissolution of solid substances
The main area for dissolution rate studies during the early phases of drug devel-
opment is the evaluation of different solid forms of a drug (e.g. salts, solvates/
hydrates, polymorphs, amorphous forms) or the effects of particle size. This sec-
tion focuses on the solid phase and on the importance of solid-state properties 
on the dissolution rate of APIs.
2.2.1 Classification of solid substances
Drug molecules in a crystal are held together by weak forces such as hydrogen 
bonds, forces of attraction between polarisable units or by van der Waals forces 
(Brittain and Byrn, 1999; Grant, 1999). In the crystalline state the atoms, ions, or 
molecules are arranged in a periodic, three-dimensional (3D) pattern to form 
unit cells, which, when repeated in regular array, constitute crystal lattices. Poly-
morphs are solid crystalline phases of a compound, resulting from at least two 
2 THEORY AND LITERATURE REVIEW
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different molecular arrangements of the compound in the solid-state (Grant, 
1999; Bernstein, 2002). When solvent molecules are a part of the crystal lattice, 
the solid is called solvate, and if the incorporated solvent is water, the term 
hydrate is used (Morris, 1999). Amorphous forms are non-crystalline materials 
which lack a definite long-range order (Hancock and Zografi, 1997). The change 
in crystal structure often, but not always, translates to a change in the external 
shape (morphology), termed crystal habit. 
Differences in packing properties as well as in lattice energies and entropies 
(see next chapter) between the solid forms give rise to differences in physico-
chemical properties (thermodynamic, spectroscopic, kinetic, surface and me-
chanical) that may significantly affect the performance of an API (Haleblian 
and McCrone, 1969; Grant, 1999). These properties are of great importance for 
the pharmaceutical industry, since the differences in, for example, flowability 
or tabletting properties may induce difficulties in manufacturing processes. On 
the other hand, the physical and sometimes also chemical stability may depend 
on the solid form (Byrn et al., 2001). A major concern, however, is that varying 
dissolution rates possible for different structures of the same drug entity can, 
in turn, lead to varying degrees of bioavailability and result in a therapeutic 
failure (Haleblian and McCrone, 1969; Brittain and Grant, 1999; Vippagunta et 
al., 2001). Classical API examples are carbamazepine (Meyer et al., 1992) and 
ritonavir (Chemburkar et al., 2000). Therefore, regulatory guidelines require the 
pharmaceutical industry to characterize the physicochemical properties of APIs 
and to evaluate their impact on dissolution behaviour (Byrn et al., 1995; ICH, 
1999; Huang and Tong, 2004; FDA, 2007).
2.2.2 Stability relationships between solid phases – meaning for 
solubility and dissolution
Thermodynamically, only one solid form is stable at constant temperature and 
pressure. All the other forms tend to transform to the stable solid form. The 
Gibbs free energy of a polymorph is defined as:
 
 
 
TSHG −=               (2)
where H is the enthalpy, T is the absolute temperature and S is the entropy. 
The stable solid form has the lowest Gibbs free energy. Two polymorphs are 
classified as enantiotropes if a reversible transition occurs at definite transition 
temperature (Tt), below the melting point of either polymorphic form (figure 
3a). Each enantiotrope has its own range of stability and at transition tempera-
ture the Gibbs free energies of the two phases are equal, meaning that the two 
phases are in equilibrium. Examples of enantiotropic APIs are carbamazepine, 
metochlopramide and tolbutamide (Giron, 1995; Burger and Ramberger, 1979; 
Yu, 1995). In a monotropic system only one polymorph is stable at all temper-
atures (i.e. has the lowest Gibbs free energy) (figure 3b). Monotropic system 
has been reported for e.g. chloramphenicol palmitate (Giron, 1995). Solids that 
are thermodynamically unstable, but may exert kinetically stable behaviour for 
6some time at given conditions, are said to be metastable. Amorphous form of 
solid (i.e. form that possess no long-range order) is the most energetic form, 
which, above its glass transition temperature (Tg) tends to crystallize to a crystal-
line form. 
Figure 3. Energy diagram for (a) enantiotropic and (b) monotropic systems. Modified from 
Burger and Ramberger, 1979.
 Different lattice free energies also give rise to differences in solubilities be-
tween the solid forms (Brittain and Grant, 1999). The solid having higher lattice 
free energy (i.e. the less stable form) dissolves faster, because the release of 
a higher amount of stored lattice free energy will increase the solubility and, 
hence, the driving force for dissolution. Hydrates are very common among 
the pharmaceutical APIs - about one-third are capable of hydrate formation 
(Griesser, 2006). The hydrates are usually more stable and less soluble than their 
anhydrous counterparts at temperatures regularly used in solubility and dissolu-
tion testing (25–37°C) (Shefter and Higuchi, 1963; Yalkowsky, 1981). The stabil-
ity of hydrate crystal structures is related to hydrogen bonding ability of water 
molecules, which contributes to stabilizing the crystal lattices (Gillon et al., 2003; 
Morris, 1999). The solubility diagram for a hydrate-anhydrate system can be ex-
pressed by using a van’t Hoff Plot (figure 4) (Shefter and Higuchi, 1963; Byrn 
et al., 1995). The general rule that lower dissolution and absorption rates are 
obtained with hydrate forms has been found to hold true for e.g. theophyl-
line (de Smidt et al., 1986; Zhu et al., 1996), ampicillin (Zhu and Grant, 1996) 
and glutethimide (Khankari and Grant, 1995), but opposite observations also 
exist, for example in the case of erythromycin (Allen, 1978). Amorphous forms 
of pharmaceuticals have been found to be much more soluble than their crystal-
line counterparts (Hancock and Parks, 2000). The determination of meaningfull 
experimental solubilities for amorphous materials has been found, however, 
difficult because of the tendency to rapidly revert to the crystalline state upon 
exposure to small quantities of solvent.
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2.2.3 Phase transformations & 
dissolution
Pharmaceutical development of metast-
able forms with higher thermodynamic 
activity is sometimes desired because the 
enhanced biopharmaceutical properties 
they possess as a result of higher solubili-
ties and faster dissolution rates. In other 
cases, metastable forms are unaccept-
able because of transformation to ther-
modynamically more stable forms during 
processing (e.g. wet granulation, drying 
or milling) (Shekunov and York, 2000; Wik-
ström et al., 2005; Jørgensen et al., 2004; 
Airaksinen et al., 2005, Aaltonen et al., 2007), storage (Byrn et al., 1995; Byrn, 
2001), or, perhaps most importantly, during dissolution in the aqueous environ-
ment of the GI tract (Kahela et al., 1983; Meyer et al., 1992).  The most serious 
consequence of these transformations is that the bioavailability and therapeutic 
efficacy may be endangered, since the crystallization of a stable form will inter-
fere with the dissolution kinetics and deplete the drug concentration available 
for absorption. Experimental interpretation of in vitro dissolution or solubility of 
drugs capable of hydrate formation is quite a challenging task, and a strong need 
exists for new applications (Shefter and Higuchi, 1963; de Smidt et al., 1986; Zhu 
et al., 1996; Rodriquez-Hornedo and Murphy, 1999; Tian et al., 2007). Although 
solid-solid transformations are also possible for the pharmaceutical APIs, this sec-
tion focuses on describing transformations mediated by the solvent.
Crystallization (supersaturation, nucleation and crystal growth)
Transformation to a new solid phase is a kinetic crystallization process which can 
be described by two steps, nucleation and crystal growth (Myerson, 1999). Su-
persaturation, i.e. the state where the concentration of solute exceeds the equi-
librium concentration, sets up the thermodynamic potential for nucleation and 
crystal growth. Numerous methods exist to create supersaturation: evaporation 
of solvent, dissolution of metastable solid phases, or methods that regulate the 
solute solubility, including change in temperature, pH, solvent composition, and 
enzyme activation. 
Crystal nucleation occurs when dissolved molecules aggregate in a supersatu-
rated solution into organized clusters. Nucleation can be divided into two cat-
egories: (1) homogenous nucleation, which occurs only in bulk solutions having 
large volumes, and (2) heterogeneous nucleation, which occurs at interfaces or 
surfaces (Mullin, 2001). Nucleation rate can be controlled by viscosity, tempera-
ture, degree of supersaturation, solubility and solid-liquid interfacial tension 
(Mullin, 1993; Myerson, 1993). For example, increasing solubility increases the 
rate of nucleation (at constant supersaturation) by increasing the probability of 
intermolecular collisions. 
1/temperature (K)
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Figure 4. Solubility diagram for anhydrate-
hydrate system. Modified from Shefter 
and Higuchi, 1963. 
8Growth of crystals consists of several stages (Rodriquez-Hornedo and Mur-
phy, 1999): (1) transport of molecules from the bulk solution to a site at the 
crystal surface (i.e. impingement site), (2) absorption of the growth unit onto 
the impingement site, (3) diffusion from impingement site to a growth site, 
and (4) incorporation into crystal lattice. Crystal growth can be either: (1) vol-
ume-diffusion controlled, if diffusion of the solute from the bulk solution to the 
crystal surface is the rate-limiting step, or (2) surface integration controlled, if 
incorporation into a crystal lattice is the slowest process (Nyvlt et al., 1985; My-
erson, 1993). Crystal growth can be affected by supersaturation, temperature, 
additives or solvent(s). For a diffusion controlled process, the hydrodynamic con-
ditions, such as flow rate or stirring rate, may have a remarkable effect.
Crystal morphology
The morphology of a crystal (i.e. crystal habit) is determined by the relative 
growth rates of individual crystal faces; the ones that have the most influence 
are the slow growing faces. A classification of crystal morphologies is given in 
the United States Pharmacopoeia (USP) (USP XXXI, 2008). Morphology changes 
are due to different crystal faces that grow at different rates depending on the 
internal factors such as crystal defects, or external ones such as temperature, sol-
vent conditions or presence of additives (Garti and Zour, 1997). Crystals having 
elongated, acicular or plate-like habits may produce difficulties in their phar-
maceutical behaviour in, for example, flowability, compressibility, wettability or 
dissolution (Shekunov and York, 2000; Davey et al., 2002; Garnier, 2002). 
Effect of additives
Additives, such as surfactants regularly used for solubilising poorly water-solu-
ble drugs, are known to affect the crystallization. Surfactants can solubilize hy-
drophobic drugs through micellar solubilization (Mukerjee and Cardinal, 1976; 
Luner et al., 1994; Yalkowsky, 1999; Alvarez-Nunez and Yalkowsky, 2000, Li and 
Zhao, 2003; Chen et al., 2003), which usually results in higher solubilities and dis-
solution rates. Depending on the solubilization capacity, surfactants have shown 
to induce more rapid achievement of the supersaturated state and, thereby, 
faster onset of nucleation (Luhtala, 1992; Rodriquez-Hornedo and Murphy, 
2004). The surfactant micelles may also either promote the crystallization of a 
stable solid form by acting as templates for nucleation and growth (Weissbuch 
et al., 1991; Canselier, 1993), or retard the crystallization when increase in solu-
bility is compensated by intermolecular interactions between the surfactant and 
crystallizing solute (Garti et al., 1982; Furedi-Millhofer et al., 2002). If surfactants 
adsorb or interact with specific crystal faces during growth, crystal morphology 
may be changed (Hendriksen et al., 1998; Sinclair, 2000; Rodriquez-Hornedo and 
Murphy, 2004). A schematic representation of the change in crystal morphology 
due to inhibition of growth of a specific crystal face is presented in figure 5. 
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Transformation during dissolution; 
stages and controlling processes
Solvent-mediated transformations 
occurring during the dissolution of 
a metastable solid can be described 
by three stages (Cardew and Davey, 
1985): (1) First stage is a pre-trans-
formation stage during which the 
metastable solid dissolves until the 
solubility limit of the stable form has been exceeded (i.e. the supersaturated 
state is created); (2) During the transformation stage nucleation and growth 
occur and supersaturation with respect to the stable solid form is maintained by 
dissolution of both the forms; (3) After the transformation is over (steady-state 
stage), the crystals of the stable form dissolve at a constant rate. The driving 
force for the solvent-mediated transformation is the solubility difference be-
tween the metastable and stable phases. 
A model has been developed and used to explain the solvent-mediated trans-
formation kinetics (Cardew and Davey, 1985;Davey et al., 2002). For a dissolu-
tion controlled process, rate constant kdissolution<<kgrowth, and the dissolution of 
the metastable phase is slower than the nucleation and growth of the stable 
phase, resulting in an initial decline in the supersaturation as crystallization of 
the stable phase rapidly depletes the concentration in solution (figure 6). When 
kdissolution>>kgrowth, the process is growth controlled and the supersaturation re-
mains close to the initial supersaturation as the metastable form dissolves. 
2.2.4 Dissolution testing of solid 
forms
The effect of solid form properties on 
dissolution rate is usually tested with 
pure APIs by studying the surface spe-
cific dissolution, termed intrinsic disso-
lution, of a material (Nicklasson, 1992; 
Gibson, 2000). The basis of the intrinsic 
dissolution method is that the surface 
area of the compact is kept constant 
during the testing (USP XXXI, 2008). 
The advantage of the method is that 
particle size effects can be excluded, 
which may hide the actual solid form 
effects on the dissolution rate. The 
dissolution rate is expressed as the 
amount of drug dissolved per unit surface area per time (e.g. mg/(min cm2). 
The rotating disc method is the most popular technique for testing the intrinsic 
dissolution rate and the use in preformulation phase dissolution studies is well 
documented (Levich, 1962; Grijseels et al., 1981; Nicklasson et al., 1981; Grijseels 
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Figure 5. Morphology change due to additive 
interaction with crystal face a. Higher growth 
rate of face b results in an elongated habit.
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Figure 6. Supersaturation dependence on the 
dissolution of a metastable and growth of 
stable crystal form during solvent-mediated 
transformation. Modified from Davey et 
al.,1986.
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et al., 1983; Nicklasson and Magnusson, 1985; Nicklasson et al., 1988; Nicklasson, 
1992 USP XXXI, 2008). The dissolution rate in a centrically mounted rotating disc 
can be expressed according to Levich’s equation (1962):
 
 
 
2/126/13/261.0/ ω⋅⋅⋅⋅⋅= − rCvDdtdm s ,            (2)
where D is the diffusion coefficient, v is the kinetic viscosity of the solvent, Cs 
is the aqueous solubility, r is the radius of disc and ω is the angular velocity. Ac-
cording to this equation, constant laminar flow hydrodynamics can be assured 
if a linear relationship with zero intercept is obtained between the dm/dt and 
ω . Although the determination of intrinsic dissolution from the compressed 
discs is well standardized (USP XXXI, 2008), it still encompasses many uncertain-
ties that may affect interpretation of the results. For example, with solids that 
undergo solvent-mediated transformation during dissolution testing, it may be 
unachievable to detect which of the solid phases is determining the dissolu-
tion rate by measuring only the dissolved concentrations in the liquid state. The 
subchapters below also address a few uncertainties related to sample prepara-
tion.
Preferred orientation
Crystal growth and habit were addressed earlier in this literature review. Pre-
ferred orientation, also called texture, usually results when powders with highly 
asymmetric crystal habits (e.g. plate-like or needle-like habits) tend to adopt 
a preferred alignment in a sample or, more usually, due to the different treat-
ments, such as compression (figure 7), formation (drawing, stretching or rolling), 
or annealing (Kocks et al., 2000). In a highly texturized sample, only certain crys-
tal faces are represented on the tablet surface. Since dissolution can be roughly 
considered as the inverse process of the crystal growth (e.g. slower growing face 
= slower dissolution rate), the surface specific dissolution rate from tablets con-
sisting of randomly distributed isotropic crystals can be assumed to differ from 
that of texturized tablets (Watanabe et al., 1982; Danesh et al., 2001; Prasad et 
al., 2002). 
 
Figure 7. Compacts with randomly distributed (left) and preferentially oriented crystals 
(right).
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crystal imperfections/crystallinity
Prior to the intrinsic dissolution measurements, APIs are compressed into com-
pacts. Depending on the mechanical stress applied, molecular disordering from 
a large number of crystal imperfections, such as vacancies (point defects), dis-
locations (line defects) or grain boundaries (surface defects), can be induced 
to reduced crystallinity (amorphization) (Grant and York, 1986; Fabbiani and 
Pulman, 2006). The dissolution phenomenon exhibits the same symmetry as the 
crystal structure itself and, thereby, depends on the type of forces that exist 
between the atoms and molecules in the crystal lattice. Crystal lattice imperfec-
tions increase the dissolution rate by assisting the weakening of forces holding 
the crystals together (Burt and Mitchell, 1981). Large disordered areas on the 
surface of the compacts may act as high energy spots, where wettability and 
dissolution is enhanced.
2.3 dissolution as a prognostic in vivo tool
One of the most important purposes of the in vitro dissolution testing is to pre-
dict in vivo performance of formulated drug products. This section focuses on 
absorption limitations, GI conditions for dissolution and in vivo prognostics of in 
vitro dissolution media.
2.3.1 Limiting factors in oral absorption
Bioavailability (BA) is defined as the rate and extent to which the active sub-
stance is absorbed from a drug product and becomes available at the site of ac-
tion (FDA, 2000). Processes that may influence the BA are highlighted in figure 
8.
Figure 8. Processes influencing the bioavailability (BA) of therapeutic APIs. 
According to the following equation, the oral bioavailability can be simpli-
fied to be determined by three major components:
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)1()1( HGa EEFBA −⋅−⋅= ,            (3)
where Fa is the fraction of the dose that is absorbed across the apical cell 
membrane of the enterocyte and EG and EH are the fractions that are extracted 
over the gut and the liver, respectively (FDA, 2000). The Fa may be limited by 
several different sources of reactions in the GI lumen and at the apical side of 
the enterocyte membrane: (1) the drug is not released from the formulation 
over an appropriate time frame, (2) the drug is decomposed in the GI tract or 
a nonabsorbable complex is formed, (3) the drug does not permeate efficiently 
enough across the gut wall or it is transported back to GI lumen by efflux trans-
porters, or (4) the drug is metabolised presystemically, for example in the gut 
wall (Macheras et al., 1995).
2.3.2 Biopharmaceutics classification system
The Biopharmaceutics Classification System (BCS), proposed by Amidon et al. in 
1995, is a simplified model which classifies APIs into four basic groups according 
to their solubility and permeability (figure 9). Equilibrium solubility is consid-
ered high if the highest dose of the drug can be dissolved in 250 ml of buffer 
solution over entire physiological pH range (pH 1-7.5 (FDA, 2000) or pH 1-6.8 
(EMEA, 2002). A drug is assigned as highly permeable if the fraction absorbed 
after oral administration is >90% (FDA, 2000). Since processes in body liquids are 
usually kinetic in nature (not equilibrium), also a requirement for rapid dissolu-
tion has been established (>85% of the dose should be dissolved in 30 minutes). 
These classification criteria have been criticized as being overly conservative and 
relaxed criteria for solubility (soluble in 500 ml) (Polli et al., 2004), permeability 
(fraction absorbed >85%) (Yu et al., 2002) and dissolution (>85% dissolved in 60 
min) (Polli et al., 2004) have been proposed.
Figure 9. Biopharmaceutics Classification System.
applications of Bcs in pharmaceutical industry
(1) The main aim of the BCS is to provide a regulatory tool for replacing bioavail-
ability/ bioequivalence (BA/BE) studies by prognostic in vitro dissolution tests, 
e.g. in the case of approving generic drug products or with Scale-Up and Post 
Approval Changes (SUPACs) (FDA, 2000; EMEA, 2002). The BCS allows a biow-
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aiver for class I drugs (high solubility, high permeability, rapid dissolution) with 
good stability in the GI tract and a wide therapeutic window (Amidon et al., 
1995; Lennernäs and Abrahamsson, 2005). In the future, also BCS class III APIs 
should be considered as biowaiver candidates (Blume and Schug, 1999; Polli, 
2004; Kortejärvi et al., 2007).
(2) BCS can also be used as a simple tool in early drug development to deter-
mine the rate-limiting step in oral absorption process and, thereby, to assist in 
selecting new drug candidates and further guiding the formulation decisions 
(Abrahamsson and Lennernäs, 2004; Lennernäs and Abrahamsson, 2005; Len-
nernäs et al., 2007). Increased risk for successful drug product development can 
be considered with BCS class II and IV APIs, which are usually quite lipophilic 
and, thus, sparingly water soluble. For BCS class II drugs, oral absorption is pre-
dominantly limited by their (a) inability for the whole dose to be dissolved in 
the gastrointestinal (GI) aqueous contents or (b) their too slow dissolution rate 
to occur in the proper time frame (Dressman et al., 1998). Mediated by dissolu-
tion, the BA of class II drugs is influenced by physicochemical, physiological and 
formulation parameters, and can often be increased by different formulation 
methods (e.g. nanoparticles, microemulsions, semisolids), solid phase treatment 
approaches (e.g. micro/nanonization, amorphization, solvate/hydrate forma-
tion) or by co-digested fatty meal (Gibson et al., 2000; Lennernäs and Abraham-
sson, 2005; Porter et al., 2007; Stegman et al., 2007). 
(3) One use of BCS is evaluation whether in vitro–in vivo (IVIVC) correla-
tion would be achievable. A point-to point relationship, i.e. level A IVIVC (FDA, 
1997b) can usually be found between the in vivo and in vitro dissolution, if the 
dissolution is the determining step for absorption, as in the case of class II drugs 
or controlled release formulations. 
(4) For immediate release dosage forms, the BCS provides a good starting 
point for dissolution method development. For class II (and sometimes class 
IV) drugs, use of biologically relevant dissolution media may assist in achieving 
IVIVC, or at least an in vitro–in vivo association (Dressman and Reppas, 2000; 
Nicolaides et al., 2001). For BCS I and III drugs, IVIVC is usually not achievable 
because permeability or gastric emptying is the rate limiting step for absorption. 
In those cases, a simple quality control method using plain buffer solutions is 
suitable throughout the lifecycle (Klein et al., 2005).
2.3.3 Gastrointestinal conditions for solubility and dissolution
The in vivo solubility and dissolution rate are affected by GI conditions such as 
pH, GI fluid composition and hydrodynamics (Lennernäs et al., 2007). The GI tract 
consists of three major anatomical regions, the stomach, the small intestine and 
the colon, which all have their unique features for dissolution and absorption. 
Gastric fluids are acidic in fasted state (median pH 1.7), but are buffered to 
higher pH values at fed state (median pH 5.0) (Dressman et al., 1990; Dressman 
et al., 1998; Efentakis and Dressman, 1998). In the small intestine, the pH varies 
from pH 6.0 to 6.5 at fasted state and from pH 5.0 to 5.5 at fed state (Kalantzi 
et al., 2006). The pH is especially important for the solubility and dissolution of 
14
proteolytic drugs with pKa values within the physiological pH range. Some for-
mulation excipients may also show pH dependent behaviour.
 Dosage form transit time is influenced by intestinal motility and fluid flow. In 
the fasted state, motility is controlled by migrating myoelectric complex (MMC), 
which cycles over 90–120 min pushing any residual contents from the stomach 
to the upper intestine (Kellow et al., 1986). In the presence of food, irregular 
contractions mix the intestinal contents, but the activities in the stomach are de-
layed. This may appear as delayed absorption of weak acids and enteric coated 
formulations, since the absorption from stomach is generally minimal and oc-
curs mainly across the large surface of intestine (Davis et al., 1986; Gruber et al., 
1987). 
The maintenance of sink conditions for dissolution in vivo is dependent on 
the available fluid volume. Fluid volumes are controlled by oral intake of liquid 
or food, secretions and permeability across the GI wall. The fluid volumes in 
fasted GI tract vary from 20-50 ml in stomach to 120-350 ml in the intestine (Dil-
lard et al., 1965; Dressman et al., 1998). 
Considering poorly water-soluble, lipophilic drugs, the major dissolution en-
hancing factors in the GI tract are wetting and solubilization by physiological 
amphiphiles. The main endogenous micelle forming surfactants in the GI fluids 
are bile salts. In the small intestine, the bile salts may incorporate phospholipids 
and lipid digestion products (e.g. free fatty acids, monoglycerides, cholesterol) 
into their micellar structure and form various colloidal phases (e.g. mixed mi-
celles, vesicular structures, and emulsion droplets) that are capable of efficient 
solubilization of molecules (Carey and Small, 1972; Gardiner and Small, 1976; 
Mithani et al., 1996; Charman et al., 1997; Porter and Charman, 2001; Wiedman 
et al., 2002; Kossena et al, 2003).
2.3.4 Biorelevant in vitro dissolution media
The prediction of in vivo dissolution strongly depends on how well the in vitro 
dissolution test represents the conditions in the GI tract. The consistence of hu-
man intestinal fluids (HIF) has been investigated in fasted and fed states (table 
2). Although the HIF is the most representative medium for in vivo situation, its 
use is limited by difficulties in collecting the aspirates, in generating reproduc-
ible results and by high costs (Dressman, 2007). The use of canine intestinal fluid 
(CIF) as an alternative to HIF is limited by higher bile salt levels compared to HIF 
(Kostewicz et al., 2002; Kalantzi, 2006a). Tubes and various imaging techniques, 
to directly monitor drug dissolution in vivo, have been used to increase under-
standing and to develop better predictive models (Bonlokke et al., 2001; Persson 
et al., 2005; Persson et al., 2006; Kalantzi et al., 2006b).
Biorelevant media simulating the gastric and intestinal fluids (IF) have suc-
cessfully been utilized to better reflect the wetting and solubilization power of 
the in vivo GI fluids (Naylor et al., 1993; Naylor et al., 1995; Galia et al., 1998; 
Nicolaides et al., 1999; Pedersen et al., 2000a; Vertzoni et al., 2004; Vertzoni et 
al., 2007), and in some cases IVIVC has been established (Nicolaides et al., 1999; 
Dressman and Reppas, 2000; Nicolaides et al., 2001; Sunesen et al., 2005b; Wei 
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and Löbenberg, 2006). The first compositions of the most widely used IFs, FaSSIF 
(Fasted State Simulated Intestinal Fluid) and FeSSIF (Fed State Simulated Intesti-
nal Fluid), were designed 10 years ago on the basis of bile salt and phospholipids 
concentrations and the pH in human GI tract, and buffer capacities measured 
in a fistulated dog model (Galia et al., 1998; Dressman et al., 1998). In vitro dis-
solution rates in these media may not, however, always correlate with aspirated 
fluids (Pedersen et al., 2000b; Kostewicz et al., 2002). Lately, the composition 
of FaSSIF and FeSSIF has been redefined to better correspond to the fasted and 
fed conditions in the proximal gut (Jantratid et al., 2008) (table 3). For exam-
ple, monoglycerides and fatty acids, important digestion lipids that affect the 
solubilization and dissolution in the fed state, are now included in the FeSSIF. 
Complexicity and high costs of these physiologically based media, however, limit 
their wider use for industrial drug development purposes and development of 
simpler media for in vivo prediction is strongly warranted. 
Table 2. Characteristics of human intestinal fluid, HIF.
HIF Fasted Fed
Bile salts (mM)
(mean ± SD)
2.0 ± 1.9a  (n=9) Jejunum               
2.9 ± 2.9b  (n=37) Jejunum            
5.3 ± 4.7c (n=16) Jejunum             
5.9 ± 1.8d (n= 7) Duodenum
14.7 ± 8.9c (n=16) Jejunum            
16.2 ± 1.5e (n=13) Jejunum 
10.1 ± 4.2d (n=7) Duodenum
Phospholipids (mM)
(mean ± SD)
0.2 ± 0.07f Jejunum 3.0 ± 0.3 f   (n=3) Jejunum
4.31 g (pooled, n=12) Duodenum
6.3 ± 1.0d (n=7) Duodenum
Monoglycerides (mM) 5.4 ± 4.5d, 3.9 ± 1.7e
Free fatty acids (mM) 23.5h 28.3 ± 4.1 h 
Cholesterol (mM) 1.5 ± 0.12 h
pH 6.63 ± 0.23i 5.1-5.4 j
a Pedersen et al., 2000b, bLindahl et al., 1997, cTangerman et al., 1986, dArmand et al., 1996, eRauterau 
et al., 1981, fPersson et al., 2005, gKalantzi et al., 2006a, hMansbach et al., 1975, iKostewicz et al., 2002, j 
Dressman et al., 1990.
Table 3. Compositions of FaSSIF and FeSSIF according to Jantratid et al., 2008.
fassif fessif
Bile salt (sodium taurocholate) (mM) 
Phospholipid (lecithin) (mM) 
Maleic acid (mM)
Sodium hydroxide (mM)
Sodium chloride (mM)
Glyceryl monooleate (mM) 
Sodium oleate (mM) 
pH
Osmolality (mOsm kg-1)
Buffer capacity (mmol l-1 ΔpH-1)
3
0.2
19.12
34.8
68.62
6.5
180 ± 10
10
10
2
55.02
81.65
125.5
5
0.8
5.8
390 ± 10
25
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3 aims of the study 
The topic of this thesis was to combine solid phase analyses with dissolution 
determinations and, thereby, to provide in-depth understanding of the effects 
of solid state properties on the intrinsic dissolution rate of APIs. In addition, an 
objective was to find a simplified dissolution media in order to predict and com-
pare the in vivo behaviour of BCS class II drugs. The specific aims of the thesis 
were the following:
• To study the effects of preferred orientation of crystals on IDR and, in this 
context, to clarify the extent of influence that sample preparation exerts on 
intrinsic dissolution studies (I)
• To explain the changes in intrinsic dissolution rate due to solvent-mediated 
phase transformations by simultaneously measuring the drug concentrations 
in the dissolution media and quantifying solid phase compositions of the dis-
solving solids in situ with Raman spectroscopy (II, III, IV)
• To investigate the effects of hydrodynamics on the solvent-mediated trans-
formation kinetics by comparing two intrinsic dissolution testing devices with 
different liquid flow characteristics (III)
• To gain molecular level insight into the influence of biorelevant dissolution 
medium, FaSSIF, on the solvent-mediated transformation behaviour (II, IV)
• To evaluate dissolution media with synthetic surfactants for their ability to 
enhance drug dissolution similarly to FaSSIF, and to predict drug absorption 
in vivo (V)
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4 Experimental
4.1 Materials
Used materials and references to corresponding publications are summarized in 
table 4.
Table 4. Materials used in this thesis work.
Material Publication source
Acetylsalicylic acid (ASA) I Shandong Xinhua, China
Tolbutamide (TB) I Dipharma Francis, France
Carbamazepine (CBZ) I, IV Fabrika Italiana Sintetici, Italy
Entacapone I Orion Corporation, Fermion, Finland
Theophylline (TP) II, III BASF, Ludwigshafen, Germany
Nitrofurantoin (NF) II Sigma-Aldrich, Seelze, Germany
Spironolactone V Pharmacia Ltd., United Kingdom
Danazol V Yangzhou Pharmaceutical co., Ltd., China
N74 (phase I substance) V Orion Corporation, Orion Pharma, Finland
Spiridon® tablets V Yangzhou Pharmaceutical co., Ltd., China
Danol® capsules V Sanofi-Synthelabo, United Kingdom
N74 capsules V Orion Corporation, Orion Pharma, Finland
Ethanol (96% v/v) I, II, III, IV Primalco, Rajamäki, Finland
Sodium taurocholate 
(extracted from ox)
IV, V Sigma-Aldrich Chemie GmbH, Germany
Egg phosphatidylcholine 
(lecithin)
IV, V Lipoid E PCS, n.l.t. 96% pure, Lipoid GmbH, 
Germany
Sodium lauryl sulphate (96% 
pure)
V Fluka, Bucfs, Switzerland
Tween 80 (per sinteci) V Merck-Schicherdt, Germany
Sodium dihydrogen 
phosphate, sodium 
chloride, sodium 
hydroxide, phosphoric acid, 
hydrochloric acid (analytical 
grades)
I,V Merck KGaA, Germany
Phosphate buffers pH 5.5 
(USP), 6.5 (USP), 6.8 (Ph.Eur.)
I, V FF Chemicals, Finland
Simulated Gastric and 
Intestinal Fluids (USP grade, 
without enzymes)
III, IV Oy Reagena Ltd., Finland
Preparation of the studied solids
TP monohydrate (II, III), NF monohydrate (II) and CBZ dihydrate (IV) were crys-
tallized from aqueous solutions. Anhydrous forms used in the studies were ob-
tained by dehydration of their respective monohydrate forms at 100°C under 
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reduced pressure (72 mbar, for 24 hours). For texture measurements, the tex-
turizing batches were obtained by one of the following means: sieving (ASA), 
recrystallizing from ethanol: drug solution by drowning out with water (TB), by 
dissolving drug powder into etanol and drying at 80°C, or as received (entaca-
pone). Batches with less-texturizing behaviour were produced by grinding the 
texturizing batch with mortar and pestle.
Preparation of the dissolution media
Fasted State Simulated Intestinal Fluid (FaSSIF) containing biological amphiphiles, 
sodium taurocholate and lecithin, was prepared according to Galia et al. (1998) 
(IV, V). The synthetic surfactant solutions studied in publication V were prepared 
by adding various concentrations (w/v %) of either SLS or Tween 80 into sodium 
based phosphate buffer solution pH 6.8 (Ph. Eur.). Phosphate buffer solutions 
pH 5.5 (USP) (I), pH 6.5 (USP) (I) and pH 6.8 (Ph. Eur.) (V), Simulated Gastric Fluid 
(SGF) pH 1.2 (III) and Simulated Intestinal Fluid (SIF) (IV) were used as received. 
4.2 Methods
Experimental methods and equipment used in this thesis and references to the 
corresponding publications are summarized in table 5.
4.2.1 Dissolution methods
Dissolution rates of pure APIs in publications I–IV were studied using intrinsic 
dissolution methods. Two devices were used (III, figure 1): standardized rotat-
ing disc (RD) (USP) (I, III) and channel flow cell (CFC) apparatus introduced for 
pharmaceutical purposes more recently (Peltonen et al., 2003) (II, III, IV). In both 
methods only one face of the powder compact is in contact with the dissolution 
medium. XRPD was used to confirm that no phase changes or reduced degrees 
of crystallinity were induced during the preparation of compacts. To assure sink 
conditions and the best possible discrimination power of the dissolution meth-
ods, composition of dissolution media, pH (range 1.2-6.8) and rotation (rpm)/
flow (range 9.0-20.0 ml/min) rate were chosen in each case based on the pKa 
and solubility properties of the studied drug.
Dissolution studies of the drug formulations in FaSSIF and conventional sur-
factant media were performed with a flow through dissolution method de-
scribed in USP (V). Flow rate of 8 ml/min was used since velocities (2 cm/min us-
ing Ø 22.6 mm cells) close to those reported to exist in GI tract (1.5 cm/min) were 
achieved (Sunesen et al., 2005b). Dissolution equipment was used as an open 
loop to assure the maintenance of sink conditions with the tested poorly soluble 
drugs. Collected fractions were filtered (0.45 μm) and in some cases centrifuged 
(2500 rpm for 5 min) prior to analysis.
Quantification of the dissolved amounts were performed either with UV-Vis-
spectrophotometer (I-IV) or by reverse-phase HPLC (Agilent 1100) with UV de-
tector (V). 
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Table 5. Methods and techniques used in this work.
Method/equipment Publication equipment
X-ray powder diffractometry 
(XRPD)
I–IV Bruker AXS, Bruker, Germany/
Philips X’Pert Pro II, PANalytical, The Netherlands/
Philips X’Pert Pro MPD, PANalytical, The Nether-
lands
Raman spectroscopy II, III, IV Spectrometer: Control Development Inc., USA 
(IN), probe: InPhotonics, USA (MA), laser: Star-
bright 785 S, Torsana Laser Technologies, Den-
mark/
VTT Optical Instrument Centre, Finland
Scanning electron microscopy 
(SEM)
I–IV Scanning microscope JSM-840A, Jeol, Japan with 
ADDA and Image AnalySIS software, Olympus 
Soft Imaging Solutions GmbH, Germany
Intrinsic dissolution measure-
ments
I–IV Rotating disc, USP/
Channel flow cell (Peltonen et al., 2003)
Surface tension measurements V Delta-8 automatic multichannel micro tensiom-
eter with 8 parallel balances, Kibron Inc., Finland
Hydrodynamic particle size 
measurements/Dynamic light 
scattering
V Zetasizer Nano ZS, Malvern Instruments Ltd., 
United Kingdom
Solubility measurements V Modified shake-flask method 
Flow through dissolution meas-
urements
V Dissolution tester with a  piston pump CY7-50, 
Sotax, Switzerland
4.2.2 Evaluation of the dissolution media
Surface tensions of the dissolution media were measured with 96-well plates 
using the Du Noüy maximum pull force method. Critical micelle concentrations 
(CMC) were derived from the surface tension measurements. The hydrodynamic 
size (d(H)) of the micelles in each media was evaluated by dynamic light scat-
tering (DLS) measurements at detection angle of 173° and wavelength of 633 
nm. The translational diffusion coefficients (D) were converted to hydrodynamic 
sizes of the particles using Stokes-Einstein relation (V, equation 1). The micelle 
sizes were presented as intensity distributions.
4.2.3 Solid phase characterization 
Solid forms were verified after crystallization, grinding, compression and dissolu-
tion testing using X-ray powder diffraction equipped with theta-theta goniom-
eter (I-IV). The measurements were performed in symmetrical reflection mode 
using Göbel mirror bent multiplayer optics. Degree of crystallinity was checked 
after compression by Full Width at Half Maximum (FWHM) comparisons. The 
texture, in publication I, was characterized with three different methods: (1) 
pole figure analysis (with Schultz reflection geometry), (2) crystal structure cal-
culations and (3) peak intensity comparison. For the last two methods, the or-
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dinary laboratory diffractometer with Bragg-Brentano geometry was used, but 
for the pole figure measurements the diffractometer was equipped with special 
(ATC-3) goniometer. 
 Solid state compositions during intrinsic dissolution testing were monitored 
in situ with CCD-Raman spectrometers equipped with fibre optic probes. With 
the CFC dissolution device, a Raman spectrometer (resolution 5 cm-1) equipped 
with diode laser having operational wavelength of 785 nm and spot size of 200 
μm was used (II, III, IV). With the RD dissolution equipment, the spectrometer 
operated at a higher wavelength (830 nm) and collected information from a 
larger area (spot size 600 μm) (III). The Raman spectral intensities were normal-
ized by standard normal variate (SNV) transformation (Barnes et al., 1989). For 
the purposes of this study, quantification using a univariate method was suf-
ficient: A ratio of test peak and reference peak areas was calculated and the 
results were correlated with hydrate contents (w/w%) in the samples. The main 
differences in measuring the configurations were that, in RD, the signal was 
measured through the dissolution medium, the glass wall of the vessel and the 
water bath, whereas in CFC, the measurement was conducted through a quartz 
sight window modified for the Raman probe and through a much thinner layer 
of dissolution medium (III, figure 1)
Scanning electron microscopy (SEM) was utilized for crystal morphology 
(habit) examination prior to the texture measurements (I) and during the sol-
vent-mediated phase conversions (off-line) (II-IV). The excess dissolution media 
was immediately removed from the compact surfaces and samples were sput-
tered with a layer of cold under vacuum prior to the measurements.
4.3 Molecular modelling
Hydrogen bonding capability between the API and amphiphile molecules was 
inspected by docking simulations (IV). Calculations of minimum energy struc-
tures (MMFF94x force field) of isolated molecules were performed within MOE 
modelling environment (Chemical Computing Group Inc., Montreal, Canada, 
2007). 
4.4 data processing
Kinetics of the solvent-mediated phase conversions were evaluated by fittings 
using Weibull distribution combined with Nonlinear Mixed Effects Model ap-
proach (NONMEM) (Davidian and Giltinan, 1995) (III, equation 1, and IV). Rate of 
conversion functions were derived from the fitted Weibull models, and the de-
scriptive solid transformation parameters were solved from the resulting func-
tions according to equations 2–4 presented in publication III.
Intrinsic dissolution concentration data were analysed by moving the fit of a 
simple linear regression (III, IV). The series of regression coefficients were con-
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sidered estimates of the rate of dissolution. Flow-through dissolution profiles 
were evaluated using analysis of variance to compare the dissolution efficiencies 
(DE%) (Khan and Rhodes, 1975). Fractional dissolution rates (Lánský and Weiss, 
2003) for the first order kinetic model were calculated from the flow through 
dissolution data and the obtained rate constants were used as input parameters 
for plasma profile simulations (V, equations 2-4). All model fittings were per-
formed with SAS software (version 9.1.3, SAS Institute Inc., USA).  
4.5 simulation of plasma profiles
The in vivo predictability of the different ‘biorelevant’ dissolution media were 
tested by comparing the observed and simulated plasma profiles (V). The ob-
served plasma profiles were obtained from in vivo studies with fasted beagle 
dogs. Simulation of plasma profiles was performed using a compartmental 
absorption and transit model (CAT) (Yu et al., 1996) (software Stella 8.1, isee 
systems, Lebanon, NH, USA) (figure 10). This model combined the following: 
1) the basic pharmacokinetic parameters (bioavailability (BA), distribution rate 
constants (K12, K21), elimination rate constant (Kel), absorption rate constant (Ka) 
and volume of distribution (Vss)) calculated from the in vivo data obtained af-
ter administration by intravenous injection, oral solution and oral capsule; 2) 
the physiological parameters of canine GI tract (gastric emptying and intestinal 
transit rates and liquid volumes in the stomach and intestine) obtained from 
the literature; and 3) the dissolution rate constants (input parameters) derived 
from the in vitro flow through dissolution data. The observed versus simulated 
plasma profiles were compared by means of AUC and Cmax values (with predic-
tion errors (PE%)).
Figure 10. The structure of the CAT simulation model illustrating the rate constants for gastric 
emptying (Kge) (for capsule and solution), dissolution (Kd), intestinal transit (Kt), absorption 
(Ka), distribution (K12, K21) and elimination (Kel) (modified from publication V). 
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5 results and discussion 
5.1 intrinsic dissolution
The intrinsic dissolution method is based on the idea that the surface area of the 
dissolving sample is kept constant during testing (Levich, 1962; USP XXXI, 2008). 
Although considered as quite a simple method, serious sources of errors exist 
that may affect the concentration gradient at the solid-liquid interface and lead 
to errors in the evaluation of the dissolution rate. Potential factors that may 
affect the interpretation of the intrinsic dissolution (figure 11) were studied in 
publications I–IV and are discussed in the next chapters.
Figure 11. Factors that may affect the intrinsic dissolution rate of drugs.
5.2 Preferred orientation of crystals 
As highlighted in the theoretical part, the preferred orientation of drug crystals 
with highly asymmetric habits (e.g. plate-like or needle-like) can be induced, 
for example, when preparing powder compacts for the intrinsic dissolution 
studies. In publication I, the surface specific dissolution rates were studied from 
less-texturized and texturized acetylsalicylic acid (ASA), tolbutamide (TB), car-
bamazepine (CBZ) and entacapone compacts. The degree of texture in the sam-
ples was characterized with three different X-ray-based methods: (1) pole figure 
analysis, (2) crystal structure calculations, and (3) peak intensity comparison.
 The trends in results from the different texture characterization methods 
used were shown to correspond well with each other (I, table 2). This observation 
confirmed the fact that no special X-ray goniometers are needed, since a very 
good indication of the texture can be obtained with normal Bragg-Brentano 
X-ray diffraction equipment. All the studied plate- or needle-like APIs, except 
CBZ, were found to texturize strongly during compression. Also, the ground 
powder samples were texturized, but the degree of preferred orientation was 
Sample preparation
-crystallinity
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-flow/mixing
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significantly lower. This was due to the decreasing particle size, which allowed 
more random orientation of particles in the compacts. The intrinsic dissolution 
rate of the samples compacted from ground powder was in all cases slightly 
higher than the dissolution rate of their more texturized counterparts. However, 
the only statistically significant difference in the intrinsic dissolution rates was 
shown in case of tolbutamide samples (figure 12). 
Figure 12. The preferred orientation illustrated as pole figure profiles measured from the 
crystal plane (200) (sharp downward trend in profile corresponds to a high degree of texture 
in the sample) (left) and the intrinsic dissolution rates of the tolbutamide samples (right). 
Modified from publication I.
It is generally expected that the direction in which the crystals grow most 
intensively is also the direction in which the dissolution is the highest. Although 
this theory has been proved with single crystals (Watanabe et al., 1982; Danesh 
et al., 2001; Prasad et al., 2002), it was not supported with the compacted ma-
terials. The most important source responsible for the ‘hidden’ effect of texture 
on dissolution was considered to be the grinding process. Grinding might both 
increase (more crystal strains) and decrease (less effective surface area) the dis-
solution rate (Burt and Mitchell, 1980). Therefore, Tenho et al. (2007) conducted 
another study, in which all the samples had intact particle surfaces after crystal-
lization. The findings were similar to this study, but the difference between the 
intrinsic dissolution rates of texturized and less-texturized samples was shown 
to be clearly higher. It should, however, be noted that those dissolution studies 
were performed with the channel flow cell device, which has different hydro-
dynamic characters than the rotating disc apparatus used in the present study. 
To summarize, the preferred orientation of crystals during compact preparation 
can be considered as a possible source of error when performing intrinsic dis-
solution experiments. 
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5.3  In situ solid phase analysis during intrinsic dissolution 
testing
The intrinsic dissolution rate of drugs is usually directly proportional to ther-
modynamic solubility (Nicklasson et al., 1981; Gu et al., 1987), but deviations 
from this general rule exist (Allen et al., 1978; Kahela et al., 1983; Laihanen et 
al., 1996). As shown in figure 11, there are several factors that may affect the 
intrinsic dissolution rate of APIs. In the search for cause, the traditional measure-
ment of drug concentrations in the liquid phase can only show that there is a 
change between samples, but not what and/or why it has changed. Therefore, 
simultaneous measurements of the solid phase composition and the dissolved 
concentrations (figure 13) were applied in publications II, III and IV. These stud-
ies, where Raman spectroscopy was used in situ to explain the problematic disso-
lution behaviour of drugs that underwent solvent-mediated conversion during 
the tests, are discussed in this section.
Figure 13. Simultaneous measurement of the solid and liquid phases during intrinsic dissolu-
tion testing.
5.3.1 Solid phase analysis using Raman spectroscopy
Raman spectroscopes were interfaced with the channel flow cell (CFC) (II, III, IV) 
and rotating disc (RD) (II) devices to detect the hydrate formation during the dis-
solution of theophylline (TP) (II, III), nitrofurantoin (NF) (II) and carbamazepine 
(CBZ) (IV) anhydrate forms (III, Fig.1). In each case, Raman was able to distinguish 
between the anhydrate and hydrate forms of the studied drugs. The in situ 
evaluation of the solid phase conversion was shown, however, to be much more 
challenging in the case of RD. Figure 14 shows the changes at the wavenumbers 
where clear spectral differences existed during the dissolution experiments. In 
the case of CFC, TP anhydrate (A) had distinct peaks at 1671 and 1714 cm-1 and 
TP monohydrate (M) had a characteristic peak at 1694 cm-1. In the RD, the phase 
change was quantified in the range of 1150–1200 cm-1 due to decreased signal-
to-noise ratio at the high wavenumber end of the spectra. The intensity of the 
Raman signal was considered to be decreased as a result of light interactions 
while passing through the layers of water and glass between the sample and 
the probe. The channel flow cell equipment was modified with a quartz sight 
window for the Raman probe, which helped to obtain better quality spectra 
throughout the spectral range.
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When dealing with spectroscopic data, a decision between univariate and 
multivariate quantification techniques has to be made. Multivariate methods 
are advised only in cases of very noisy and cross-correlated data. Since our data 
had, in each case, distinct anhydrate and hydrate peaks with sufficiently high 
signal-to-noise ratios, simple rationing of the test and reference peak intensities 
(II) or peak areas (III, IV) was utilized. Despite the interfering sources observed 
in RD, Raman spectroscopy was has been shown to be a powerful tool to detect 
the solid phase changes during dissolution in aqueous surroundings. Since Ra-
man spectroscopy mainly detects symmetric vibrations of nonpolar and aromatic 
groups in the drug molecules, water has a weak Raman scatter signature. With 
regards to this, it is superior compared to other spectroscopic techniques, such 
as Near Infrared (NIR) spectroscopy, for which the spectra is dominated by vibra-
tions associated with O-H bonds and is thereby influenced by the presence of 
water molecules. In the field of pharmaceutical applications, this unique char-
acter of Raman spectroscopy has previously been utilized to detect solid state 
changes during e.g. wet-granulation (Jørgensen et al., 2002; Airaksinen et al., 
2003; Wikström et al., 2005) and aqueous crystallization (Agarwal and Berglund, 
2003; Ono et al., 2004; Caillet et al., 2006). 
Figure 14. Characteristic peaks used in the quantification of TP (A) to TP (M) phase conversion 
during dissolution tests in RD (left) and CFC (right). Modified from publication III.
5.3.2 Connection between the solid phase composition and 
dissolution rate
Complex dissolution behaviour of drugs that are capable of hydrate formation 
has been an unsolved area in the pharmaceutical field. Previous studies have 
combined off-line solid phase analytics with in vitro dissolution, which, how-
ever, are incapable of accurately quantifying the conversion kinetics (Kahela et 
al., 1983; Kaneniwa et al., 1987; Kobayashi et al., 2000; Tian et al., 2007). In this 
thesis, the in situ measured Raman data helped to explain the changes in dis-
solution rates of TP (II, III), NF (II) and CBZ (IV) anhydrate forms. Results discussed 
here were all measured in simple aqueous media using the channel flow cell 
dissolution device. 
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A nonlinear mixed effects model approach was utilized to distinguish the 
three stages of solvent-mediated conversion from the solid phase data (Cardew 
and Davey, 1985). Figure 15 demonstrates the effects of the increasing hydrate 
ratio on the intrinsic dissolution rate of the initially anhydrous TP (A) compacts 
(with the pre-transformation, transformation and steady state stages) (III).  At 
the pre-transformation stage, the dissolution rate of TP (A) compact was higher 
than the dissolution rate of TP monohydrate (M). The dissolution rate of initially 
anhydrous compact was decreased as the amount of monohydrate form was 
increased. During the transformation, dissolution of both the forms and crystal-
lization of the monohydrate occurred. Once the conversion was complete, the 
dissolution rate of the initially anhydrous surface became constant (linearized 
phase). At the steady state stage, TP (A) was no longer present and, therefore, 
only TP (M) dissolved. Transformation was seen in SEM figures as rapid needle-
like growth of monohydrate crystals on the surfaces of the compacts (II, figure 3 
and III, figure 6). This clear increase in the effective surface area was seen in the 
dissolution results; despite the fact that the Raman results indicated ~100% con-
version, the dissolution rate of the initially anhydrous compact was still slightly 
higher than the dissolution rate of the TP (M) compacts.
Unlike with TP, the correlation between the solid phase transformation and 
changes in intrinsic dissolution rates were not evident with NF. Although the 
dissolution rate was changed several times during the test, there was no distinct 
decrease in the dissolution rate during the transformation stage (II, figure 5). 
Variation of the dissolution rate was likely caused by several overlapping fac-
tors, e.g. the changing anhydrate/monohydrate ratio and the decreasing rate of 
hydrate formation.
           
Figure 15. Connection between hydrate formation (primary y-axis) and intrinsic dissolution 
rate (secondary y-axis) of TP anhydrate (left). More detailed description of dissolution 
behaviour during conversion is shown on the right. Modified from publication III.
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The poor water solubility and low dissolution rate of CBZ resulted in 20-fold 
and 200-fold slower rates of hydrate formation compared to NF and TP, respec-
tively (IV). Like with TP, Raman data explained the dissolution behaviour of the 
CBZ forms extremely well. However, whereas the surfaces of TP and NF compacts 
were transformed completely to monohydrate form, Raman results indicated 
a 25% unconverted CBZ anhydrate (form III) portion at the steady state stage 
of conversion (IV, figure 5). Moreover, during the first few hours, the dissolu-
tion rate of dihydrate compact in simple buffer media (SIF) was almost equal to 
the dissolution rate of the initially anhydrous compact (IV, Fig. 3). SEM figures 
showed several layers of needle-like growth on the surface of the compacts (IV, 
figure 4). This extensive crystal growth may have impeded the SIF contact with 
the solid CBZ form III, resulted in a decreased dissolution rate and, correspond-
ingly, retarded the growth of further needles. These hypotheses agree well with 
other recent studies (Rodriquez-Hornedo and Murphy, 2004; Tian et al., 2006; 
Tian et al., 2007). Furthermore, the needle-like crystal growth also changed the 
effective surface area throughout the tests, and this may partly explain the dis-
solution behaviour observed with CBZ and NF. 
5.3.3 Effect of hydrodynamics
In publication III, the effect of hydrodynamics on the solvent-mediated trans-
formation kinetics of TP was tested with RD and CFC devices. Raman spectro-
scopic measurement showed distinctly different timescales in transformation 
behaviour between the two devices. Modelling of the kinetics confirmed the 
fact that the transformation in the CFC clearly followed the first order kinetics, 
but the transformation kinetics in the RD was S-shaped. Figure 16 shows the 
conversion-rate profiles derived from these models. The extremely rapid onset 
of transformation in the CFC was connected to a three-fold higher intrinsic dis-
solution rate during the pre-transformation stage. Thus, the higher dissolution 
rate promoted the attainment of supersaturation prior to the nucleation and 
growth. The dissolution dependence on the angular velocity showed, accord-
ing to Levich’s theory (Levich, 1962), that the transport process in the RD could 
be accelerated by increasing the agitation speed. SEM figures confirmed the 
dependence of crystal growth rate on the dissolution device used (III, figure 6). 
This dependence on the hydrodynamic conditions show that the diffusion of the 
solute from the bulk solution to the crystal surface was the rate-limiting step, 
not the incorporation into a crystal lattice. 
The hydrodynamics of a system is known to largely affect the diffusion con-
trolled processes (Nyvlt et al., 1985; Myerson, 1993). Observed differences in 
transformation kinetics were, hence, related to dissimilar hydrodynamics and dif-
fusion characteristics in the two set-ups, which were shown to control both the 
dissolution and crystallization processes. Direct comparison of the hydrodynam-
ics provided by these two devices (e.g. by using dimensionless Reynolds numbers) 
was complicated by the diverse nature of the liquid flow characteristics. The RD 
provides radial and tangential motions of the liquid flow and a boundary diffu-
sion layer is formed at the centre area (Grijseels et al., 1982), whereas the lami-
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nar liquid convection in the CFC device 
directed parallel to the solid surface 
prevents the formation of a uniform 
diffusion layer at the solid-liquid inter-
face (Compton et al., 1993). Based on 
this study, no recommendations were 
given of whether an RD or CFC device 
is preferred for the intrinsic dissolution 
evaluation of metastable drugs, How-
ever, it is obvious that the selection of 
the dissolution equipment and flow/
agitation rate remarkably affects the 
transformation (in case of diffusion-
controlled crystal growth), and the 
dissolution results gained.
5.3.4 Effect of additives
Surfactants are frequently used in the dissolution testing of poorly soluble drugs 
(USP XXXI, 2008). Surfactants can either promote or inhibit the crystal growth 
processes depending on their solubilizing capacity and interaction potential 
(Luhtala, 1992; Bujan et al., 2001; Rodriquez-Hornedo and Murphy, 2004). In IV, 
the effect of physiological surfactants, sodium taurocholate (STC) and lecithin, 
was evaluated on solvent-mediated transformation behaviour of CBZ.
Dissolution of CBZ form III was clearly promoted by increased wetting and 
solubilization by the STC-lecithin micellar aggregates (IV, table 1). Raman spec-
troscopic analysis of the solid phase data showed, however, that the maximum 
rate of transformation was almost equal in the presence and absence of STC 
and lecithin. The results from both Raman and off-line XRPD measurements 
indicated approximately one-half CBZ form III unconverted portion after 19 
hours of dissolution (steady state stage). The X-ray peak intensity comparison 
also revealed a significant preferred orientation effect (figure 17); based on the 
solved crystal structure of CBZ dihydrate, the most texturized plane in SIF (a 
medium without surfactants) was plane (020) (corresponding to peak at 12.3° 
(2θ)). In FaSSIF, however, the plane (-111) was the most preferred one (corre-
sponding to the peak at 19.5° (2θ)). This clear indication of different CBZ dihy-
drate crystal habits among the two media was confirmed by SEM-micrographs, 
which showed needle-like crystal habits in SIF, but in FaSSIF principally plate-like 
shaped clusters were found (figure 17). These results are in line with other re-
cent studies (Rodriquez-Hornedo and Murphy, 2004; Sinclair, 2000) and indicate 
the fact that intermolecular interactions (e.g. hydrogen bonds, electrostatic at-
tractions) between the surfactant additives (e.g. STC) and the preferred crystal 
plane (-111) were formed. This hypothesis was further tested by docking simula-
tions. A great number of low energy conformations were observed that enabled 
the generation of CBZ-STC structures via several hydrogen bonds (distance 2Å). 
Strong H-bonding may have 1) impeded the medium contact with the CBZ and 
slowed down the dissolution, 2) changed the growing habit, and 3) limited the 
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Figure 16. Anhydrate to monohydrate 
conversion-rate profiles of theophylline in 
rotating disc (RD) and channel flow cell (CFC) 
devices. Modified from publication III.
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conversion rate to a constant level. Depending on the type of surfactant used in 
the dissolution medium and the drug substance studied, surfactant micelles may 
also promote the crystallization of the stable solid form by acting as templates 
for nucleation and growth (Weissbuch et al., 1991; Canselier, 1993). Therefore, 
in order to be able to relate the in vitro dissolution results of metastable solids 
to their in vivo behaviour, it is essential that the studies are initiated in a physi-
ologically relevant medium.
 
figure 17. X-ray diffractograms of CBZ compacts before and after dissolution tests (peaks 
indicating preferred orientation are circled) (left) and SEM figures taken during CBZ dissolu-
tion in SIF (needle-like habit) (a-c) and FaSSIF (plate-like habit) (d-f) (right). Modified from 
publication IV.
5.3.5 Uncertainties related to in situ Raman measurements 
There are few challenges related to the measuring configuration of Raman 
(when used in situ during intrinsic dissolution testing), which need to be re-
solved in future to achieve even more accurate quantitative results. The acces-
sible depth of Raman measurement varies from a few hundred micrometers 
(semitransparent materials like tissue) to one millimetre (pharmaceutical tab-
lets) (Matousek, 2007). This implies that, in our studies, Raman was not able to 
measure only the outermost layers where dissolution, nucleation and growth oc-
curred. This may partly explain the detected unconverted portions of CBZ form 
III in IV. The depth of Raman measurement has not, however, been a greatly 
discussed issue, and more detailed investigations should be performed in the fu-
ture. Surface-sensitive methods could help to avoid this problem. Another chal-
lenging issue is related to the fact that the focus of the Raman measurement 
was influenced to some extent by thick dihydrate crystal growth on the surfaces 
of the compacts. Moreover, future studies should also concentrate on increasing 
the effective sample volume, for example by using optics that can be focused to 
a much larger area. Raman microscopy could, on the other hand, help to visual-
ize the situation in situ, whether or not the spot is focused on the site where the 
growth is occurring.
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5.4 In vitro media for simulating dissolution in vivo 
5.4.1 Evaluation of in vivo prognostic dissolution media
Biorelevant media simulating the fasted and fed states in the small intestine 
have lately been developed to increase the in vivo predictability of in vitro dis-
solution tests (Galia et al., 1998; Sunesen et al., 2005b; Wei and Löbenberg, 2006; 
Lue et al., 2008; Jantratid et al., 2008). Most well-known of these media are 
perhaps FaSSIF and FeSSIF, which contain biologically relevant amounts of physi-
ological amphiphiles, bile salts and lecithin. The cost and complexity of these me-
dia, however, limit their extensive use for industrial applications. In V, dissolution 
enhancement of three BCS class II drug formulations (Danol®, Spiridon® and N74 
capsule (compound under phase I development)), was compared between FaSSIF 
and various concentrations of conventional surfactants (SLS and Tween 80).
The studied dissolution media were shown to deviate quite largely in their 
physicochemical properties. Surface tensions, indicating the wetting ability of 
the drug surfaces, ranged between ~34-46 mN/m, surface tension of SLS being 
the closest to that prevailing in human intestinal fluids (~34 mN/m (Pedersen et 
al., 2000)). The micelle size of sodium taurocholate (STC)-lecithin mixed micelles 
was 5-fold and 18-fold larger than the micelle size obtained for Tween 80 and 
SLS, respectively. The diffusivity of micelles, which affects the overall dissolu-
tion rate, decreased in the order SLS > Tween >> STC-lecithin. For danazol, a 
0.07% Tween 80 gave equal dissolution efficiency (DE%) with FaSSIF, whereas 
for less hydrophobic N74, 0.07% Tween 80 and 0.1% SLS were the closest, but 
still over-estimated the DE% in FaSSIF. The least hydrophobic drug, spironolac-
tone, showed almost no affinity to the surfactant micelles, and, thus, no dissolu-
tion enhancement in any of the studied media. The level of dissolution enhance-
ment was clearly related to the magnitude of solubilization by the surfactant 
micelles, driven by the hydrophobicity of the drug (V, figure 2a-c and table 1). 
This agrees well with previous studies which have shown correlation between 
the increasing octanol-water partition coefficient (logP) and the increasing af-
finity to bile salt micelles (Mithani et al., 1996; Wiedman et al., 2002). Moreo-
ver, the results indicated differences in the payload of drug molecules between 
the SLS, Tween 80 and STC-lecithin micelles (Crison et al., 1996). The fact that 
very different combinations of properties between the media were shown to 
produce similar dissolution enhancement levels in FaSSIF and drug-specific con-
centrations of SLS or Tween 80 underlines the importance of the evaluation 
of surfactant-facilitated dissolution as a whole. Although it is obvious due to 
the specificity of the drug-surfactant interactions that the in vivo prognostic 
amounts of synthetic surfactants have to be adjusted drug-specifically, this study 
shows the great potential of substituting FaSSIF with simple and cost-effective 
conventional surfactant media.
5.4.2 Prediction of absorption 
The field of computer simulations with physiologically based pharmacokinetic 
absorption models has been covered in several articles (Plusquellac et al., 1999; 
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Norris et al., 2000; Yokoe et al., 2003). The compartmental absorption and transit 
model (CAT) predicts the Fa of drugs on the basis of GI tract physiology, in vitro 
dissolution data and physicochemical drug-related parameters (e.g. solubility, 
permeability) (Yu et al., 1996). In the CAT model, absorption and transit proc-
esses are described with nine compartments (stomach, colon and small intestine 
as seven compartments) (Yu and Amidon 1999). In V, an advanced CAT model 
(Agoram et al., 2001), in which basic pharmacokinetic parameters describing 
drug distribution and elimination were integrated into the model, was used 
to predict plasma concentration-time profile of N74 (chapter 4.5, figure 10). 
Pharmacokinetics of N74 was studied with dogs and thus, also the physiological 
part of the model was adapted to correspond to canine GI tract conditions. The 
dissolution rate constants calculated from the in vitro dissolution data described 
in chapter 5.4.1 were used as input parameters in the simulations.
The simulations indicated that 0.1% SLS was the best predictor to the in vivo 
pharmacokinetic parameters, Cmax and AUC (figure 18, V table 5). The fact that 
FaSSIF, which is designed on the basis of human GI fluids, gave lower Cmax and 
AUC than observed in vivo could be related to the physiological differences be-
tween the human and canine GI tract. For example, dogs reportedly have higher 
small intestinal bile salt levels, which, due to the increased solubilization capac-
ity, may lead to higher amounts absorbed (Carlsson et al., 2002). Based on these 
results, it is obvious that the typical amounts of conventional surfactants in dis-
solution testing monographs (from 0.5% up to 2.0% (w/v) (USP XXXI, 2008)) 
grossly overestimate the solubility from the in vivo point of view.
Figure 18. Observed versus simulated plasma profiles of N74. Modified from publication V.
Overall,	pharmacokinetic simulations always include some uncertainties. In 
this study, the slight inaccuracy in prediction of Tmax was probably related to 
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the high variation between dogs, which complicated the definition of repre-
sentative pharmacokinetic parameters (absorption, distribution, elimination) 
for the simulation model. Also the use of non-sink (> 30% of saturation solubil-
ity) in vitro dissolution data may have added some uncertainty to the simulation 
model. However, these simulations, which consider the input phase as a result 
of processes taking place in various compartments, can generally be considered 
to give a much more precise estimation of the input profile than the traditional 
convolution approach (Yu and Amidon, 1998). Due to increasing interest in ex-
ploitation of canine data for construction of simulation models, future efforts 
should be directed towards transforming the nine-compartment CAT-model to 
better correspond to the GI physiology in dogs.
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6 conclusions
The main conclusions of this thesis are:
1. Quantitative solid phase analysis can be performed during intrinsic 
dissolution testing of APIs using Raman spectroscopy in situ. 
Simultaneous analysis of liquid and solid phases enables science-based 
explanation(s) for changes in the dissolution rate, e.g. due to hydrate 
formation. This information will serve the pharmaceutical industry in 
drug candidate selection as well as in explaining and controlling the 
behaviour of APIs in the final drug products.
2. Careful selection of the dissolution equipment and flow/agitation rate 
is crucial for intrinsic dissolution testing of APIs, as hydrodynamics was 
shown to remarkably affect the solvent-mediated transformations, 
and, thereby, the dissolution results gained.
3. The preferred orientation of drug crystals, which may occur during the 
preparation of powder compacts for intrinsic dissolution studies, has 
only a minor effect on the interpretation of dissolved concentrations. 
4. Physiological amphiphiles, as bile salts in a biorelevant dissolution 
medium, FaSSIF, may interact with dissolving APIs via hydrogen 
bonding and change the solvent-mediated crystallization behaviour. 
Therefore, in order to be able to relate the in vitro dissolution results 
of metastable solids to their in vivo behaviour, it is essential that the 
studies are initiated in a physiologically relevant medium.
5. To predict in vivo behaviour of BCS class II drugs, simple and cost-
effective conventional surfactant media were shown to be potential 
substitutes for the more complex, physiologically based FaSSIF. The 
use of biorelevant amounts of conventional surfactants in dissolution 
media will not only be economic during the various steps of drug 
development, but could also place the quality control dissolution 
tests into a more meaningful context.
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